Two candidacies will stand in the elections to select the first board of directors of CataloniaBio & HealthTech: one headed up by Jaume Amat, founder and CEO of Specipig, and the other by Albert Gallart, CEO of Grupo Pulso. For the past four years, Amat has been a member of the CataloniaBio board, while Gallart was president of the HealthTech Cluster (the two organisations have merged to create the new CataloniaBio & HealthTech). Voting will take place on 8 February at the general members’ assembly. 

Jaume Amat’s list features Lluís Chico, managing partner at NEOS Surgery, as first vice-president; Maribel Bergés, co-founder and CFO of Spherium Biomed (Ferrer partner), for second vice-president; and Àngel Alonso, CEO of Vecmedical, as third vice-president. 

The candidacy led by Albert Gallart includes Sergi Rabazza, Business Division manager at Laboratorios Hartmann, as first vice-president; Félix Villar, partner at IN2, for second vice-president; and Eduard Valentí, Regulatory Affairs director and head of Pharmaceutical Quality at Esteve, as third vice-president. 

The board of directors chosen will head up the association through 2022. The president and first vice-president will swap roles after two years to make the body more participative, in line with the new bylaws.

CataloniaBio & HealthTech is the new entity after the merger of CataloniaBio and Health Tech Cluster that represents more than 170 companies, as well as collaborating stakeholders such as hospitals, research centres and universities that are leaders in R&D in biomedicine. The headquarters will be located at the Barcelona Science Park. 

Press release (in Spanish)

Photo: From left to right, Albert Gallart and Jaume Amat